Other substances

5-(butylcarbamoylamino)-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide

A naphthalene derivative.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

5-(butylcarbamoylamino)-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide is an experimental SARS-CoV-2 Papain-like protease inhibitor (Osipiuk et al., 2021).

(Structure image generated in SwissSimilarity)

 

Structure image - 5-(butylcarbamoylamino)-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide

CCCCNC(=O)NC1=CC(C(=O)N[C@H](C)C2=CC=CC3=CC=CC=C23)=C(C)C=C1

Supporting references

Link Tested on Impact factor Notes Publication date
Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
PapainLpro Small molecule Enzyme assay In vitro 		in vitro enzyme assay; Vero E6 cells; SARS-CoV-2 astrain nCoV/Washington/1/2020 12.12

Inhibits SARS-CoV-2 Papain-like protease in vitro with IC50 of ca. 16.8 μM.

 Feb/02/2021
Export (.csv)